Abnormal phenotype of bone marrow plasma cells in patients with chronic myeloid leukemia undergoing therapy with Imatinib

Leukemia Research

Volumn 34, Issue 10, 2010, Pages 1336-1339

  Carulli, Giovanni ^a   Cannizzo, Elisa ^a   Ottaviano, Virginia ^a   Cervetti, Giulia ^a   Buda, Gabriele ^a   Galimberti, Sara ^a   Baratè, Claudia ^a   Marini, Alessandra ^b   Petrini, Mario ^a  

^a UNIVERSITY OF PISA   (Italy)

^b Versilia Hospital   (Italy)

Author keywords

Globulins; Chronic myeloid leukemia; Flow cytometry; Imatinib mesylate; Monoclonal gammapathies; Plasma cells

Indexed keywords

CD19 ANTIGEN; CD56 ANTIGEN; IMATINIB; IMMUNOGLOBULIN;

ARTICLE; CHRONIC MYELOID LEUKEMIA; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG RESPONSE; FEMALE; HUMAN; HUMAN TISSUE; MALE; PHENOTYPE; PLASMA CELL; PRIORITY JOURNAL;

ANTIGENS, CD19; ANTIGENS, CD56; ANTINEOPLASTIC AGENTS; BONE MARROW CELLS; FEMALE; FLOW CYTOMETRY; HUMANS; LEUKEMIA, MYELOGENOUS, CHRONIC, BCR-ABL POSITIVE; MALE; PHENOTYPE; PIPERAZINES; PLASMA CELLS; PYRIMIDINES;

EID: 77955982144     PISSN: 01452126     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.leukres.2010.01.012     Document Type: Article

References (28)

1. Fausel C. Targeted chronic myeloid leukemia therapy: seeking a cure. J Manage Care Pharm 2007, 13:S8-S12.
2. Blay J.Y., Bonvalot S., Casali P., Choi H., Debiec-Richter M., Dei Tos A.P., et al. Consensus meeting for the management of gastrointestinal stromal tumors. Report of the GIST Consensus Conference of 20-21 March 2004, under the auspices of ESMO. Ann Oncol 2005, 16:566-578.
3. Goldman J.M., Melo J.V. Targeting the BCR-ABL tyrosine kinase in chronic myeloid leukemia. N Engl J Med 2001, 344:1084-1086.
4. Buchdunger E., Matter A., Druker B.J. BCR-ABL inhibition as a modality of CML therapeutics. Biochim Biophys Acta 2001, 1551:M11-M18.
5. Peggs K., Mackinnon S. Imatinib mesylate-the new gold standard for treatment of chronic myeloid leukemia. N Engl J Med 2003, 348:1048-1050.
6. Buchdunger E., Cioffi C.L., Law N., Stover D., Ohno-Jones S., Druker B.J., et al. The Abl protein-tyrosine kinase inhibitor, STI571, inhibits in vitro signal transduction mediated by c-Kit and PDGF receptors. J Pharmacol Exp Ther 2000, 295:139-145.
7. Cannizzo E., Carulli G., Azzarà A., Galimberti S., Zucca A., Petrini M. JAK-2V617F mutation in RARS-t: a target for Imatinib therapy?. Leukemia Res 2008, 32:1636-1637.
8. Dietz A.B., Souan L., Knutson G.J., Bulur P.A., Litzow M.R., Vuk-Pavlovic S. Imatinib mesylate inhibits T-cell proliferation in vitro and delayed-type hypersensitivity in vivo. Blood 2004, 104:1094-1099.
9. Seggewiss R., Loré K., Greisner E., Magnosson M.K., Prince D.A., Douek D.C., et al. Imatinib mesylate inhibits T-cell receptor-mediated T-cell proliferation in a dose-dependent manner. Blood 2005, 105:2473-2479.
10. Mumprecht S., Matter M., Pavelic V., Ochsenbein A.F. Imatinib mesylate selectively impairs expansion of memory cytotoxic T cells without affecting the control of primary viral infections. Blood 2006, 108:3406-3413.
11. Leder C., Ortler S., Seggewiss R., Einsele H., Wiendl H. Modulation of T-effector function by imatinib at the level of cytokine secretion. Exp Hematol 2007, 35:1266-1271.
12. Paniagua R.T., Orr S., Ho P.P., Chan S.M., Chang A., Higgins J.P., et al. Selective tyrosine kinase inhibition by imatinib mesylate for the treatment of autoimmune arthritis. J Clin Invest 2006, 116:2633-2642.
13. Steegmann J.L., Moreno G., Alàez C., Osorio S., Granda A., De La Càmara R., et al. Chronic myeloid leukemia patients resistant to or intolerant of interferon α and subsequently treated with imatinib show reduced immunoglobulin levels and hypogammaglobulinemia. Haematologica 2003, 88:762-768.
14. Cervetti G., Carulli G., Galimberti S., Azzarà A., Cannizzo E., Buda G., et al. Reduction of immunoglobulin levels during imatinib therapy for chronic myeloid leukemia. Leukemia Res 2008, 32:191-192.
15. Santachiara R., Maffei R., Martinelli S., Arcari A., Piacentini F., Trabacchi E., et al. Development of hypogammaglobulinemia in patients with imatinib for chronic myeloid leukemia or gastrointestinal stromal tumors. Haematologica 2008, 93:1252-1255.
16. Rawstron A.C., Orfao A., Beksac M., Bezdickova L., Brooimans R.A., Bumbea H., et al. Report of the European Myeloma Network on multiparametric flow cytometry in multiple myeloma and related disorders. Haematologica 2008, 93:431-438.
17. Baccarani M., Pane F., Saglio G. Monitoring treatment of chronic myeloid leukemia. Haematologica 2008, 93:161-169.
18. Haferlach C., Rieder H., Lillington D.M., Dastugue N., Hagemeijer A., Harbott J., et al. Proposal for standardized protocols for cytogenetic analyses of acute leukemias, chronic lymphocytic leukemia, chronic myeloid leukemia, chronic myeloproliferative disorders, and myelodysplastic syndromes. Genes Chromosomes Cancer 2007, 46:494-499.
19. Hughes T., Deininger M., Hochhaus A., Branford S., Radich J., Kaeda J., et al. Monitoring CML patients responding to treatment with tyrosine kinase inhibitors: review and recommendations for harmonizing current methodology for detecting BCR-ABL transcripts and kinase domain mutations and for expressing results. Blood 2006, 108:28-37.
20. Davies F.E., Rawstron A.C., Owen R.G., Morgan G.J. Minimal residual disease monitoring in multiple myeloma. Best Pract Res Clin Hematol 2002, 15:197-222.
21. San Miguel J.F., Gutiérrez N.C., Mateo G., Orfao A. Conventional diagnostics in multiple myeloma. Eur J Cancer 2006, 42:1510-1519.
22. Bataille R., Jégo G., Robillard N., Barillé-Nion S., Harousseau J.-L., Moreau P., et al. The phenotype of normal, reactive and malignant plasma cells. Identification of "many and multiple myelomas" and new targets for myeloma therapy. Haematologica 2006, 91:1234-1240.
23. Zipfel P.A., Grove M., Blackburn K., Fujimoto M., Tedder T.F., Pendergast A.M. The c-ABL tyrosine kinase is regulated downstream of the B cell antigen receptor and interacts with CD19. J Immunol 2000, 106:6872-6879.
24. Galanopoulos A., Papadhimitriou S.I., Kritikou-Griva E., Georgiakaki M., Anagnostopoulos N.I. Multiple myeloma developing after imanitib mesylate therapy for chronic myeloid leukemia. Ann Hematol 2009, 88:281-282.
25. Tzilves D., Gatopoulou A., Zervas K., Katodritou E., Patakiouta F., Tarpagos A., et al. Development of multiple myeloma in a patient with gastrointestinal stromal tumor treated with imatinib mesylate: a case report. World J Gastroenterol 2007, 13:2011-2013.
26. Garipidou G., Vakalopoulou S., Tziomalos K. Development of multiple myeloma in a patient with chronic myeloid leukemia after treatment with imatinib mesylate. Oncologist 2005, 10:457-458.
27. Mothy M., Blaise D., Olive D., Gaugler B. Imatinib: the narrow line between immune tolerance and activation. Trends Mol Med 2005, 11:397-402.
28. Jourdan M., Caraux A., De Vos J., Fiol G., Larroque M., Cognot C., et al. An in vitro model of differentiation of memory B cells into plasmablasts and plasma cells including detailed phenotypic and molecular characterization. Blood 2009, (October). prepublished online. 10.1182/blood-2009-07-235960.